Owing to the propensity of anticoagulated patients to bleed, a strategy for reversal of
anticoagulation induced by any of the common agents is essential. Many patients are …

Background: Over the last ten years, a new class of drugs, known as the direct-acting oral
anticoagulants (DOACs), have emerged at the forefront of anticoagulation therapy. Like the …

Approximately half of patients started on an oral anticoagulant in the USA now receive one
of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal …

Discussion To the authors' knowledge, this was the first reported case of the successful
treatment of andexanet alfa-associated heparin resistance by the supplementation of …

The assessment of hemostasis is necessary to make suitable decisions on the management
of patients with thrombotic disorders. In some clinical situations, for example, during …

Background The management of life-threatening bleeding in patients who are receiving
direct oral anticoagulants (DOACs) is a serious medical concern. Objective This review …

Background There are no randomized trials comparing andexanet alfa and 4 factor
prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I) …

Direct oral anticoagulants are associated with rates of major bleeding which are not
negligible, albeit lower than those associated with vitamin K antagonists. No specific …

Oral anticoagulants are the medication of choice for the prevention of stroke in atrial
fibrillation (AF) and the treatment of venous thromboembolism (VTE). Atrial fibrillation is the …

Current guidelines recommend specific antidots and PCCs in DOAC-related major bleeding.
Prospective randomized trials comparing specific vs. nonspecific hemostatic agents in the …